Sodium-glucose co-transporter 2 inhibitors: From apple tree to 'sweet pee'

Current Pharmaceutical Design

Volumn 16, Issue 34, 2010, Pages 3830-3838

  Hardman, Timothy C ^a   Rutherford, Peter ^b,c   Dubrey, Simon W ^d   Wierzbicki, Anthony S ^e  

^a Niche Science and Technology Ltd   (United Kingdom)

^b Baxter Healthcare   (Switzerland)

^c GLYNDWR UNIVERSITY   (United Kingdom)

^d HILLINGDON HOSPITAL   (United Kingdom)

^e ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Dapagliflozin; Glucose reabsorption; Phlorizin; Sergliflozin; SGLT2 inhibitors; Type 2 diabetes mellitus

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ANTIDIABETIC AGENT; ASP 1941; AVE 2268; BI 10773; BI 44847; CANAGLIFLOZIN; DAPAGLIFLOZIN; GLUCOSAMINE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; ISIS 388626; KGT 1681; LX 4211; METFORMIN; PHLORIZIN; R 7201; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG; WAY 123783; WO 200501231; WO 2005012321; YM 543;

APPLE; ARTICLE; CLINICAL STUDY; DISEASE PREDISPOSITION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; INSULIN RESISTANCE; KIDNEY FUNCTION; LONG TERM CARE; METABOLIC BALANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; URINARY TRACT INFECTION; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; PHLORHIZIN; SODIUM-GLUCOSE TRANSPORTER 2; SUBCELLULAR FRACTIONS;

EID: 79551643319     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794455111     Document Type: Article

References (66)

1. Mahmood D, Singh BK, Akhtar M. Diabetic neuropathy: therapies on the horizon. J Pharm Pharmacol 2009; 61: 1137-45.
2. Meyer C, Stumvoll M, Nadkarni V, et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998; 102: 619-24.
3. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001; 24: 382-91.
4. Meyer C, Dostou JM, Welle SL, Gerich JE. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab 2002; 282: E419-E27.
5. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodiumglucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-7.
6. McGeown JC. Master medicine: physiology: a core text of human physiology with self-assessment. 3rd ed. Philadelphia: Churchill Livingstone, 2004.
7. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280: F10-F8.
8. Zelikovic I. Aminoaciduria and glycosuria. In: Avner ED, Harmon WE, Niaudet P, Eds. Pediatric nephrology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2004; pp. 701-28.
9. Moe OW, Wright SH, Palacin M. Renal handling of organic solutes. In: Brenner BM, editor. Brenner & Rector's; The Kidney. 8th ed. Philadelphia: Saunders-Elsevier 2008; pp. 214-47.
10. Mather A, Pollock C. Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol 2010; 6: 307-11.
11. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004; 447: 510-8.
12. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987; 80: 1037-44.
13. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005; 21: 31-8.
14. Wu JS, Lever JE. Monoclonal antibodies that bind the renal Na+/glucose symport system. 2. Stabilization of an active conformation. Biochemistry 1987; 26: 5790-6.
15. Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 1987; 330: 379-81.
16. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43.
17. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-34.
18. Hardman TC, Lant AF. Relation of the sodium-lithium countertransporter to essential hypertension, diabetes and vascular risk. Philadelphia: Elsevier 1993; pp. 819-28.
19. Hardman TC, Dubrey SW, Leslie RD, Lant AF. Erythrocyte sodium-lithium countertransport activity in non-nephropathic diabetic twins. Diabetes Care 1996; 19: 32-8.
20. Vick H, Diedrich DF, Baumann K. Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am J Physiol 1973; 224: 552-7.
21. Bishop JH, Elegbe R, Green R, Thomas S. Effects of phlorizin on glucose, water and sodium handling by the rat kidney. J Physiol 1978; 275: 467-80.
22. Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320: 323-30.
23. Tsujihara K, Hongu M, Saito K, et al. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo) 1996; 44: 1174-80
24. Oku A, Ueta K, Nawano M, et al. Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol 2000; 391: 183-92.
25. Nawano M, Oku A, Ueta K, et al. Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats. Am J Physiol Endocrinol Metab 2000; 278: E535-E43.
26. Fujimoto Y, Torres TP, Donahue EP, Shiota M. Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats. Diabetes 2006; 55: 2479-90.
27. Nunoi K, Yasuda K, Adachi T, et al. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol 2002; 29: 386-90.
28. Arakawa K, Ishihara T, Oku A, et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)- glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001; 132: 578-86.
29. Ueta K, Ishihara T, Matsumoto Y, et al. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005; 76: 2655-68.
30. Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-800.
31. Washburn WN. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Pat 2009; 19: 1485-99.
32. Washburn WN. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem 2009; 52: 1785-94.
33. Macey RI, Farmer RE. Inhibition of water and solute permeability in human red cells. Biochim Biophys Acta 1970; 211: 104-6.
34. Hussey EK, Dobbins RL, Stoltz RR, et al. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol 2010; 50: 636-46.
35. Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009; 609: 148-54.
36. Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010; 50: 623-35.
37. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010; 38: 405-14.
38. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-9.
39. Kipnes M. Dapagliflozin: an emerging treatment option in type 2 diabetes. Expert Opin Investig Drugs 2009; 18: 327-34.
40. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-6.
41. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-7.
42. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-9.
43. Zhang L, Feng Y, List J, et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010; 12: 510-6.
44. Ferrannini E, Jimenez RS, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebocontrolled, phase III trial. Diabetes Care 2010; 33(10): 2217-24.
45. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebocontrolled trial. Lancet 2010; 375: 2223-33.
46. Wilding JP, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-62.
47. Wancewicz EV, Siwkowski A, Meibohm B, et al. Long term safety and efficacy of ISIS 388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species. 68th Scientific Sessions of the American Diabetes Association; June 6- 10, 2008; San Francisco, California. 2008.
48. Burggraaf J. Safety, tolerability and activity study of multiple doses of ISIS 388626 in healthy volunteers. 2010.
49. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-9.
50. Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract 2009; 63: 321-32.
51. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010; 56: 728-33.
52. Scheepers A, Joost HG, Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 2004; 28: 364-71.
53. Vemula S, Roder KE, Yang T, et al. A functional role for sodiumdependent glucose transport across the blood-brain barrier during oxygen glucose deprivation. J Pharmacol Exp Ther 2009; 328: 487-95.
54. Geerlings SE, Stolk RP, Camps MJ, et al. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000; 23: 1737-41.
55. Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int 2006; 69: 852-5.
56. Calado J, Soto K, Clemente C, et al. Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum Genet 2004; 114: 314-6.
57. Calado J, Soto K, Clemente C, et al. Gene Symbol: SLC55A2. Disease: familial renal glucosuria. Hum Genet 2004; 115: 170.
58. Neumiller JJ, White JR, Jr., Campbell RK. Sodium-glucose cotransport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70: 377-85.
59. Landgraf R. The relationship of postprandial glucose to HbA1c. Diabetes Metab Res Rev 2004; 20 Suppl 2: S9-S12.
60. Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab 2006; 32: 113-20.
61. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30: 1127-42.
62. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-47.
63. Goudswaard AN, Furlong NJ, Rutten GE, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004; CD003418.
64. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-63.
65. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (update). London: National Institute for Health and Clinical Excellence; 2008 Dec 5. Report No.: CG66.
66. U.K.Prospective Diabetes Study Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.